drugset / Trial / NCT00189540

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

NCT00189540 ↗

Phase 2 Completed 27 enrolled AnGes USA, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to test the hypothesis that AMG0001 treatment is safe and induces angiogenesis as detected by improved wound healing, reduction in amputation, improved pain at rest and hemodynamic measurement and to assess the effectiveness of the administrative method.

Timeline

Start
2005-08
Primary completion
2008-07
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator AMG0001 Other / unclassified 4 mg Intramuscular